{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:26:34Z","timestamp":1790616394663,"version":"4.1.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>A significant level of CD70 can be detected in various types of tumor tissues and CD27 is expressed on Treg cells, but CD70 expression is low in normal tissues. The interaction between CD70 and CD27 can stimulate the proliferation and survival of cancer cells and increase the level of soluble CD27, which is associated with poor prognosis in patients with lymphoma and certain solid tumors. Thus, it is a promising therapeutic target for the treatment of many major CD70+ cancer indications, including CD70+ lymphoma, RCC, NSCLC, HNSCC and OC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>IMM40H was obtained through hybridoma screening and antibody humanization techniques. IMM40H was evaluated for its binding, blocking, Fc-dependent effector functions and antitumor activity characteristics in various <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> systems. The safety and tolerability profile of IMM40H were evaluated through single and repeated administration in cynomolgus monkeys.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:italic>In vitro<\/jats:italic> cell-based assays demonstrated that IMM40H had considerably stronger CD70-binding affinity than competitor anti-CD70 antibodies, including cusatuzumab, which enabled it to block the interaction of between CD70 and CD27 more effectively. IMM40H also exhibited potent Fc-dependent effector functions (ADCC\/CDC\/ADCP), and could make a strong immune attack on tumor cells and enhance therapeutic efficacy. Preclinical findings showed that IMM40H had potent antitumor activity in multiple myeloma U266B1 xenograft model, and could eradicate subcutaneously established tumors at a low dose of 0.3 mg\/kg. IMM40H (0.3 mg\/kg) showed therapeutic effects faster than cusatuzumab (1 mg\/kg). A strong synergistic effect between IMM01 (SIRP\u03b1-Fc fusion protein) and IMM40H was recorded in Burkitt\u2019s lymphoma Raji and renal carcinoma cell A498 tumor models. In cynomolgus monkeys, the highest non-severely toxic dose (HNSTD) for repeat-dose toxicity was up to 30 mg\/kg, while the maximum tolerated dose (MTD) for single-dose toxicity was up to 100 mg\/kg, confirming that IMM40H had a good safety and tolerability profile.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>IMM40H is a high-affinity humanized IgG1 specifically targeting the CD70 monoclonal antibody with enhanced Fc-dependent activities. IMM40H has a dual mechanism of action: inducing cytotoxicity against CD70+ tumor cells via various effector functions (ADCC, ADCP and CDC) and obstructs the proliferation and activation of Tregs by inhibiting CD70\/CD27 signaling.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1240061","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T06:45:05Z","timestamp":1696315505000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70\/CD27 signaling"],"prefix":"10.3389","volume":"13","author":[{"given":"Song","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianze","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2005.04.004","article-title":"CD27 and CD70 in T cell and B cell activation","volume":"17","author":"Borst","year":"2005","journal-title":"Curr Opin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.12.3.341","article-title":"CD70 as a therapeutic target in human Malignancies","volume":"12","author":"Grewal","year":"2008","journal-title":"Expert Opin Ther Targets"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.07.007","article-title":"CD70: An emerging target in cancer immunotherapy","volume":"155","author":"Jacobs","year":"2015","journal-title":"Pharmacol Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3880","article-title":"Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer","volume":"6","author":"Jacobs","year":"2015","journal-title":"Oncotarget"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S44445","article-title":"Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas","volume":"6","author":"Liu","year":"2013","journal-title":"Onco Targets Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1038\/s41467-019-10588-0","article-title":"Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier function and shuttling of drugs and antibodies","volume":"10","author":"Park","year":"2019","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.21.13353","article-title":"CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase\/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase","volume":"273","author":"Akiba","year":"1998","journal-title":"J Biol Chem"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-11-2791","article-title":"CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth","volume":"72","author":"Claus","year":"2012","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.27398","article-title":"ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade","volume":"6","author":"Silence","year":"2014","journal-title":"MAbs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281563","article-title":"Results from a phase I\/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy","volume":"108","author":"Pabst","year":"2023","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15663","article-title":"Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment","volume":"114","author":"Ikezoe","year":"2023","journal-title":"Cancer Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200005000-00014","article-title":"CD70 expression in thymic carcinoma","volume":"24","author":"Hishima","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.2.710","article-title":"Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells","volume":"174","author":"Bullock","year":"2005","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-05-2883","article-title":"Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates","volume":"66","author":"Law","year":"2006","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-08-0493","article-title":"Preclinical characterization of SGN-70, a humanized antibody directed against CD70","volume":"14","author":"McEarchern","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-082578","article-title":"CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells","volume":"110","author":"Yang","year":"2007","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s42003-020-1097-8","article-title":"CD70 expression determines the therapeutic efficacy of expanded human regulatory T cells","volume":"3","author":"Arroyo Hornero","year":"2020","journal-title":"Commun Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.967147","article-title":"Novel immune checkpoint blocker approved for the treatment of advanced melanoma","volume":"3","author":"Galluzzi","year":"2014","journal-title":"Oncoimmunology"},{"key":"B21","article-title":"Opdivo (Nivolumab): Second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"B22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B23","article-title":"Production of two mAb identifying a novel activation antigen (CDw70), using spleen cells from nude mice bearing HLY-1 cell line","volume-title":"Leucocyte typing IV: white cell differentiation antigens","author":"Al Saati","year":"1989"},{"key":"B24","article-title":"Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells","volume":"147","author":"Agathanggelou","year":"1995","journal-title":"Am J Pathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10207","article-title":"CD70\/CD27 ligand, a member of the TNF family, is expressed in human brain tumors","volume":"98","author":"Held-Feindt","year":"2002","journal-title":"Int J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.05.005","article-title":"Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry","volume":"41","author":"Diegmann","year":"2005","journal-title":"Eur J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000158121.49085.ba","article-title":"CD70: a new tumor specific biomarker for renal cell carcinoma","volume":"173","author":"Junker","year":"2005","journal-title":"J Urol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3816\/clm.2007.s.023","article-title":"Novel agents in the treatment of Waldenstr\u00f6m's macroglobulinemia","volume":"7","author":"Treon","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3724\/abbs.2022141","article-title":"Identification and characterization of blocking nanobodies against human CD70","volume":"54","author":"Zhang","year":"2022","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2023.2192100","article-title":"Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer","volume":"12","author":"Flieswasser","year":"2023","journal-title":"Oncoimmunology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0613","article-title":"Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced Malignancies","volume":"23","author":"Aftimos","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1240061\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T06:45:08Z","timestamp":1696315508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1240061\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":31,"alternative-id":["10.3389\/fonc.2023.1240061"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1240061","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]},"article-number":"1240061"}}